Clinical trials · New York, NY
Breast cancer clinical trials in New York
We’re tracking 244 recruiting breast cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
New York, New YorkAges Any age - NCT05349227Recruiting
After-cancer digital coaching and wearable tracking outcomes study
This study tests a digital health coaching program (using phone/tablet check-ins and wearable data) to understand health and quality-of-life outcomes after cancer treatment. It may help you learn healthy habits and track progress over time.
New York, New YorkAges 18 years+ - NCT06721065Recruiting
Study of interpretation services for breast cancer patients
This study tests different ways of providing language interpretation during breast cancer or gastrointestinal cancer visits at MSK. It aims to improve communication for patients who prefer Spanish or Mandarin and have limited English proficiency.
New York, New YorkAges 18 years+ - NCT07294703Recruiting
Study of breast cancer risks and outcomes at MSK
This study looks at factors related to breast cancer risk and outcomes. If you are coming to MSK for a breast biopsy or are a new breast cancer patient having surgery there, you may be able to join.
New York, New YorkAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
New York, New YorkAges 18 years+ - NCT06841354RecruitingPhase 3
Sac-TMT alone or with pembrolizumab for advanced triple-negative breast cancer
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT03053193Recruiting
Testing gene activity to guide breast cancer treatment
This study links breast tumor test results from MammaPrint and optional BluePrint (and full genetic data) with real-world clinical information to understand which new gene activity patterns matter. It may help future patients by improving how doctors use these tests to guide care.
New York, New YorkAges 18 years+ - NCT06405828Recruiting
Support for women of color with advanced breast cancer
This study tests whether extra support services help women of color with metastatic breast cancer. It aims to improve access to emotional, practical, and medical resources.
New York, New YorkAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
New York, New YorkAges Any age - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
New York, New YorkAges 18–100 - NCT05095207RecruitingPhase 1/Phase 2
Abemaciclib and bicalutamide for HER2-negative metastatic breast cancer
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
New York, New YorkAges 18–90 - NCT05856773RecruitingPhase 3
Standard vs shorter radiation to lymph nodes for breast cancer
This trial compares two ways of giving radiation to the breast/chest wall and nearby lymph nodes after breast surgery: a standard schedule versus a shorter “hypofractionated” schedule. It uses proton therapy and may help reduce treatment time while still controlling the cancer.
New York, New YorkAges 19 years+ - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
New York, New YorkAges 50–70 - NCT05592938Recruiting
Partial breast re-irradiation for cancer recurrence
This trial tests a shorter course of radiation to only the part of the breast where cancer has come back. It's for women who had radiation years ago and now have a small new or recurrent tumor that can be removed by surgery.
New York, New YorkAges 18–99 - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
New York, New YorkAges 18 years+ - NCT05559164RecruitingPhase 2
Statins to protect the heart during HER2 breast cancer treatment
This trial tests whether a cholesterol medicine (a statin) can lower the risk of heart damage in people receiving HER2-targeted breast cancer therapy. If you qualify, you may be given a statin and followed with heart tests and blood work to watch for safety and benefit.
Jersey City, New JerseyAges 18 years+ - NCT06112613Recruiting
Mobile health to help with breast cancer pill-taking
This study uses text messages to help people with metastatic breast cancer remember to take their daily pills and asks about any missed doses. It aims to improve how well patients stick to their CDK4/6 inhibitor medication.
Brooklyn, New YorkAges 18 years+ - NCT06518837RecruitingPhase 2
Tirzepatide for weight loss in early breast cancer
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Newark, New JerseyAges 18 years+ - NCT07402473RecruitingPhase 2
Optimizing treatment before surgery for HER2-positive breast cancer
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Newark, New JerseyAges 18–90 - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Newark, New JerseyAges 18 years+ - NCT06139107RecruitingPhase 1
Radiation and abemaciclib plus letrozole before breast cancer surgery
This trial combines a short course of radiation before surgery with two oral medications (abemaciclib and letrozole) to treat early-stage, hormone-sensitive breast cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Belleville, New JerseyAges 60 years+ - NCT07060807RecruitingPhase 3
Study of Patritumab Deruxtecan for Advanced HR+/HER2- Breast Cancer
This trial tests a new drug called patritumab deruxtecan (a targeted therapy) for people with a common type of advanced breast cancer (HR+/HER2-). It's for those whose cancer has grown despite treatment with a CDK4/6 inhibitor plus hormone therapy.
Jamaica, New YorkAges 18 years+ - NCT06065748RecruitingPhase 3
New hormone therapy for advanced breast cancer after prior treatment
This trial tests a new oral hormone therapy, giredestrant, against a standard hormone therapy (fulvestrant) when both are given with a CDK4/6 inhibitor. It is for people with advanced ER-positive, HER2-negative breast cancer that has come back after initial hormone therapy, and who have not yet had other treatments for advanced disease.
Jamaica, New YorkAges 18 years+ - NCT06418204Recruiting
Cannabis use study for cancer patients in community clinics
This study looks at the benefits and risks of using cannabis or cannabinoids for cancer patients. It aims to help understand how these products affect symptoms and quality of life during chemotherapy or immunotherapy.
Jamaica, New YorkAges 18 years+
Hear when a new Breast cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Breast cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting breast cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 7 studies
- Rutgers Cancer Institute of New Jersey · 6 studies
- Memorial Sloan Kettering Basking Ridge · 4 studies
- Memorial Sloan Kettering Commack · 4 studies
- Memorial Sloan Kettering Monmouth · 4 studies
- Memorial Sloan Kettering Nassau · 4 studies
- NYU Langone Hospital - Long Island · 4 studies
- Chilton Medical Center · 3 studies
What taking part in a breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting breast cancer studies in New York.
Common questions
- Are there breast cancer clinical trials near New York?
- Yes. We're currently tracking 244 recruiting breast cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.